Genetic Biomarkers of Drug Response for Small-molecule Therapeutics Targeting the RTK/Ras/PI3K, P53 or Rb Pathway in Glioblastoma

Overview

Journal CNS Oncol

Specialty Oncology

Date 2016 Mar 18

PMID 26986934

Citations 17

Authors

Subramanian Venkatesan

Martine L M Lamfers

Clemens M F Dirven

Sieger Leenstra

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is the most deadly and frequently occurring primary malignant tumor of the central nervous system. Genomic studies have shown that mutated oncogenes and tumor suppressor genes in glioblastoma mainly occur in three pathways: the RTK/Ras/PI3K signaling, the p53 and the Rb pathways. In this review, we summarize the modulatory effects of genetic aberrations in these three pathways to drugs targeting these specific pathways. We also provide an overview of the preclinical efforts made to identify genetic biomarkers of response and resistance. Knowledge of biomarkers will finally promote patient stratification in clinical trials, a prerequisite for trial design in the era of precision medicine.

Citing Articles

Radiogenomics and machine learning predict oncogenic signaling pathways in glioblastoma.

Ahanger A, Aalam S, Masoodi T, Shah A, Khan M, Bhat A J Transl Med. 2025; 23(1):121.

PMID: 39871351 PMC: 11773707. DOI: 10.1186/s12967-025-06101-5.

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development.

Kwon W, Seo H, Song G, Lee M, Park W Biomedicines. 2025; 13(1).

PMID: 39857670 PMC: 11761267. DOI: 10.3390/biomedicines13010086.

Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma.

Valle-Garcia D, la Cruz V, Flores I, Salazar A, Pineda B, Meza-Sosa K Int J Mol Sci. 2024; 25(5).

PMID: 38473710 PMC: 10931459. DOI: 10.3390/ijms25052464.

Systems Medicine for Precise Targeting of Glioblastoma.

Zeng J, Zeng X Mol Biotechnol. 2023; 65(10):1565-1584.

PMID: 36859639 PMC: 9977103. DOI: 10.1007/s12033-023-00699-x.

A review for the pharmacological effects of paeoniflorin in the nervous system.

Hong H, Lu X, Wu C, Chen J, Chen C, Zhang J Front Pharmacol. 2022; 13:898955.

PMID: 36046834 PMC: 9420976. DOI: 10.3389/fphar.2022.898955.

References

Charest A, Wilker E, McLaughlin M, Lane K, Gowda R, Coven S . ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 2006; 66(15):7473-81. DOI: 10.1158/0008-5472.CAN-06-1193. View

Pandita A, Aldape K, Zadeh G, Guha A, James C . Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2003; 39(1):29-36. DOI: 10.1002/gcc.10300. View

Francis J, Zhang C, Maire C, Jung J, Manzo V, Adalsteinsson V . EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014; 4(8):956-71. PMC: 4125473. DOI: 10.1158/2159-8290.CD-13-0879. View

Akhavan D, Pourzia A, Nourian A, Williams K, Nathanson D, Babic I . De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013; 3(5):534-47. PMC: 3651754. DOI: 10.1158/2159-8290.CD-12-0502. View

Lee M, Ye A, Gardino A, Heijink A, Sorger P, MacBeath G . Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012; 149(4):780-94. PMC: 3501264. DOI: 10.1016/j.cell.2012.03.031. View

Lauchle J, Kim D, Le D, Akagi K, Crone M, Krisman K . Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009; 461(7262):411-4. PMC: 4119783. DOI: 10.1038/nature08279. View

Ozawa T, Brennan C, Wang L, Squatrito M, Sasayama T, Nakada M . PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010; 24(19):2205-18. PMC: 2947772. DOI: 10.1101/gad.1972310. View

Gallia G, Tyler B, Hann C, Siu I, Giranda V, Vescovi A . Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009; 8(2):386-93. PMC: 4498795. DOI: 10.1158/1535-7163.MCT-08-0680. View

Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes J, Gimenez-Bonafe P . Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One. 2011; 6(4):e18588. PMC: 3071734. DOI: 10.1371/journal.pone.0018588. View

10.

Kastenhuber E, Huse J, Berman S, Pedraza A, Zhang J, Suehara Y . Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathol. 2013; 127(5):747-59. PMC: 3984672. DOI: 10.1007/s00401-013-1217-3. View

11.

Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H . Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer. 2003; 37(1):58-71. DOI: 10.1002/gcc.10207. View

12.

McGillicuddy L, Fromm J, Hollstein P, Kubek S, Beroukhim R, De Raedt T . Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009; 16(1):44-54. PMC: 2897249. DOI: 10.1016/j.ccr.2009.05.009. View

13.

Lo H, Cao X, Zhu H, Ali-Osman F . Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008; 14(19):6042-54. PMC: 2707832. DOI: 10.1158/1078-0432.CCR-07-4923. View

14.

Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S . Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011; 71(24):7587-96. PMC: 3242822. DOI: 10.1158/0008-5472.CAN-11-0821. View

15.

Liu T, Koul D, Lafortune T, Tiao N, Shen R, Maira S . NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009; 8(8):2204-10. PMC: 2752877. DOI: 10.1158/1535-7163.MCT-09-0160. View

16.

Patil C, Nuno M, Elramsisy A, Mukherjee D, Carico C, Dantis J . High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. Neuro Oncol. 2012; 15(1):104-11. PMC: 3534422. DOI: 10.1093/neuonc/nos272. View

17.

Akbani R, Ng P, Werner H, Shahmoradgoli M, Zhang F, Ju Z . A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014; 5:3887. PMC: 4109726. DOI: 10.1038/ncomms4887. View

18.

Lee J, Vivanco I, Beroukhim R, Huang J, Feng W, DeBiasi R . Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006; 3(12):e485. PMC: 1702556. DOI: 10.1371/journal.pmed.0030485. View

19.

Parker B, Engels M, Annala M, Zhang W . Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 2014; 232(1):4-15. DOI: 10.1002/path.4297. View

20.

Szerlip N, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y . Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012; 109(8):3041-6. PMC: 3286976. DOI: 10.1073/pnas.1114033109. View